Magnetic resonance imaging in patients with central nervous system pathology: A comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA)

Investigative Radiology

Volumn 35, Issue 7, 2000, Pages 412-419

  Grossman, Robert I ^a   Rubin, Daniel L ^b   Hunter, George ^c   Haughton, Victor M ^d   Lee, Donald ^e   Sze, Gordon ^f   Kühn, Matthew J ^g   Maravilla, Kenneth ^h   Raymond, T U ⁱ   Heindel, Walter ^j,k   Wippold II, Franz J ^l   Leeds, Norman ^m   Zelch, James ⁿ   Jinkins, J Randy ^o   Grodd, Wolfgang ^p   Truwit, Charles ^q   Kanal, Emanuel ^r   Provenzale, James M ^s   Ramsey, Ruth ^t   Simon, Jack ^u   Brunberg, James A ^v,w   Stevens, Gary R ^x   Kristy, Rita M ^x   more..

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Good Samaritan Hospital San Jose   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ Washington Imaging Associates   (United States)

^j UNIVERSITY OF COLOGNE   (Germany)

^k UNIVERSITY OF MÜNSTER   (Germany)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF TEXAS   (United States)

ⁿ Regional Diagnostic Imaging Center   (United States)

^o UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^p UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^q UNIVERSITY OF MINNESOTA   (United States)

^r PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^s DUKE UNIVERSITY MEDICAL CENTER   (United States)

^t UNIVERSITY OF CHICAGO   (United States)

^u UNIVERSITY OF COLORADO   (United States)

^v UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x MALLINCKRODT PHARMACEUTICALS   (United States)

more..

Author keywords

Central nervous system pathology; Contrast agents; Gadolinium; Lesions; Magnetic resonance imaging

Indexed keywords

GADOLINIUM PENTETATE; GADOVERSETAMIDE;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEADACHE; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; VASOSPASM;

EID: 2442716341     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200007000-00003     Document Type: Article

References (11)

1. Adzamli K, Periasamy MP, Spiller M, Koenig SH. NMRD assessment of Gd-DTPA-bis(methoxyethylamide), (Gd-DTPA-BMEA), a nonionic MRI agent. Invest Radiol 1999;34:410-414.
2. Swan SK, Baker JF, Free R, et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection, OptiMARK®, in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 1999;9:317-321.
3. Rubin DL, Desser TS, Semelka R, et al. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (Gd-DTPA) in patients with liver pathology: Results of a phase III clinical trial. J Magn Reson Imaging 1999;9:240-250.
4. Low RN, Semlka RC, Worawattanakul S, et al. Extrahepatic abdominal imaging in patients with malignancy: Comparison of MR imaging and helical CT, with subsequent surgical correlation. Radiology 1999;210:625-632.
5. Sze G, Brant-Zawadzki M, Haughton VM, et al. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 1991;181:693-699.
6. Runge VM, Bradley WG, Brant-Zawadzki M, et al. Clinical safety and efficacy of gadoteridol: A study in 411 patients with suspected intracranial and spinal disease. Radiology 1991;181:701-709.
7. Kirchin MA, Pirovan GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): An overview. Invest Radiol 1998;33:798-809.
8. Russell EJ, Schaible TF, Williams D, et al. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: Evaluations in patients with cerebral lesions. AJNR 1988;10:53-63.
9. Goldstein HA, Kashanian FK, Blumetti RF, et al. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 1990; 174:17-23.
10. Niendorf HP, Haustein J, Cornelius I, et al. Safety of gadolinium-DTPA: Extended clinical experience. Magn Reson Med 1991;22: 222-232.
11. Kieffer S. Gadopentetate dimeglumine: Observations on the clinical research process [editorial]. Radiology 1990;174:7-8.